Using repurposed drugs to repair the damage that causes acute myeloid leukaemia
Targeting mutant NRAS in paediatric AML
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Targeting mutant NRAS in paediatric AML
RNA helicase DDX3X regulates JAK-STAT signalling in acute lymphoblastic leukaemia
Deep learning: An integrated approach to define clinical significance to components of the tumour microenvironment of rhabdomyosarcomas
Targeting Myeloid-Derived Suppressor Cells (MDSCs) and Tumour-Associated Macrophages (TAMs) with the anti-CD33 immunotoxin Gemtuzumab ozogamicin to restore anti-cancer immunity
Facing the MuSIC - identification of synergistic repurposed drug combinations as novel therapies in paediatric acute myeloid leukaemia
Targeting the Fanconi Anaemia pathyway in neuroblastoma
Overcoming drug resistance for efficacious neuroblastoma therapeutics
A genome wide study of unresectable, MYCN non-amplied, unfavourable histology neuroblastomas in patients older than 18 months of age
Teenagers and young adults with primary CNS cancers: a systematic biological characterisation